Skip to main content

Table 1 Preoperative clinicopathologic Data of Patients with CHC Who received or not postoperative TACE

From: Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis

Variable Before Propensity Matching After Propensity Matching
Without TACE (n = 184) Postoperative TACE (n = 46) P Without TACE (n = 46) Postoperative TACE (n = 46) P
Sex    0.172    > 0.99
 Men 134 38   38 38  
 Women 50 8   8 8  
Mean age (y) 52.3 ± 12.1 52 ± 10.7 0.326 53.4 ± 11.6 52 ± 10.7 0.834
HBsAg    > 0.99    0.810
 Positive 136 34   35 34  
 Negative 48 12   11 12  
HBcAb    0.666    0.231
 Positive 153 9   42 9  
 Negative 31 37   4 37  
HCV antibody    > 0.99    > 0.99
 Positive 4 1   1 1  
 Negative 180 45   45 45  
Median AFP, ng/mL 24.7 (1–80,000) 96 (1.8–46,897) 0.006 21.3 (1–30,728) 96 (1.8–46,897) 0.002
Median CEA, μg/mL 2.5 (0–274) 2.1 (0.5–70.5) 0.364 2.7 (0.1–112.4) 2.1 (0.5–70.5) 0.423
Median CA19–9, U/ml 28.1 (0–4370) 19.4 (0.2–300.1) 0.029 22 (0.5–4062.5) 19.4 (0.2–300.1) 0.023
Median bilirubin, μmol/L 11.8 (1.7–314.8) 12.9 (5.7–156.5) < 0.001 13.7 (2.4–169.3) 12.9 (5.7–156.5) 0.664
Median albumin, g/L 41 (26–55) 42 (35–66) 0.397 41 (30–48) 42 (35–66) 0.556
Median ALT, U/L 28 (5–484) 31 (5–104) 0.094 26 (11–484) 31 (5–104) 0.109
Median ALP, IU/L 89.5 (22–1413) 88.5 (46–184) 0.477 92 (25–331) 88.5 (46–184) 0.599
Median GGT, U/L 59 (3.6–1632) 80 (18–490) 0.923 75.5 (10–658) 80 (18–490) 0.273
Median platelets, 103/μL 13.7 (2.2–47.6) 16 (3.9–46.1) 0.319 15.3 (5.3–24.7) 16 (3.9–46.1) 0.171
Median prothrombin time, s 11.8 (9–17.6) 12 (10.2–13.8) 0.941 12 (10.2–14.6) 12 (10.2–13.8) 0.903
Median INR 1 (0.5–1.5) 1 (0.8–1.2) 0.227 1 (0.5–1.2) 1 (0.8–1.2) 0.065
Median tumour size, cm 5 (1–24) 7.3 (1.5–17) 0.626 6 (1.5–22) 7.3 (1.5–17) 0.384
Median tumour nodularities 1 (1–10) 1 (1–5) 0.140 1 (1–6) 1 (1–5) 0.648
Median blood loss, ml 200 (30–3500) 200 (10–2500) 0.182 200 (50–1800) 200 (10–2500) 0.480
Mean occlusion, min 6.8 ± 8.6 10 ± 1.6 0.044 5.4 ± 1.1 10 ± 1.6 0.090
Macrovascular invasion    0.041    > 0.99
 Positive 11 7   7 7  
 Negative 173 39   39 39  
Microvascular invasion    0.689    0.607
 Positive 39 11   8 11  
 Negative 145 35   38 35  
Lymphoid metastasis    0.840    > 0.99
 Positive 22 6   6 6  
 Negative 162 40   40 40  
Extrahepatic metastasis    0.719    0.646
 Positive 6 2   3 2  
 Negative 178 44   43 44  
Postrecurrent therapy    0.451    0.583
 Resection 2 1   1 1  
 TACE 27 6   10 6  
 Regional therapy 4 1   1 1  
 Chemothearpy 66 14   11 14  
 Selective internal radiation therapy 5 2   1 2  
 Stereotactic body radiation 12 5   3 5  
 Best supportive care 58 17   19 17  
  1. Data are numbers of patients. Data in parentheses are range. Mean data are±standard deviation. Regional therapy: Radiofrequency ablation and percutaneous ethanol injection
  2. HBsAg hepatitis B surface antigen, HBcAb hepatitis B core antibody, HCV hepatitis C virus, AFP α-fetoprotein, CEA carcino-embryonic antigen, CA19–9 carbohydrate 19–9, INR International normalized ratio, ALT alanine aminotransferase, GGT γ-glutamyl transpeptidase, ALP alkaline phosphatase, MVI microvascular vascular invasion
\